Dan O’Day’s $5B deal with Gala­pa­gos im­plodes as PhI­II tri­als col­lapse

Gilead’s bat­tle-scarred al­liance with Gala­pa­gos just suf­fered an­oth­er griev­ous wound.

The biotech part­ners re­port­ed Wednes­day morn­ing that they are aban­don­ing their late-stage piv­otal pro­gram for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER